TY - JOUR T1 - Autoantibodies against nephrin elucidate a novel autoimmune phenomenon in proteinuric kidney disease JF - medRxiv DO - 10.1101/2021.02.26.21251569 SP - 2021.02.26.21251569 AU - Andrew J.B. Watts AU - Keith H. Keller AU - Gabriel Lerner AU - Ivy Rosales AU - A. Bernard Collins AU - Miroslav Sekulic AU - Sushrut S. Waikar AU - Anil Chandraker AU - Leonardo V. Riella AU - Mariam P. Alexander AU - Jonathan P. Troost AU - Junbo Chen AU - Damian Fermin AU - Jennifer Lai Yee AU - Matthew Sampson AU - Laurence H. Beck, Jr. AU - Joel M. Henderson AU - Anna Greka AU - Helmut G. Rennke AU - Astrid Weins Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/02/2021.02.26.21251569.abstract N2 - Dysfunction of podocytes, cells critical for glomerular filtration, underlies proteinuria and kidney failure. Genetic forms of proteinuric kidney disease can be caused by mutations in several podocyte genes, including nephrin, a critical component of the kidney filter. In contrast, the etiology of acquired acute-onset nephrotic syndrome has remained elusive. Here we identify autoantibodies against nephrin in serum and glomeruli of a subset of adults and children with non-congenital acute nephrotic syndrome. Our findings align with published experimental animal studies and elucidate a novel autoimmune phenomenon in proteinuric kidney disease interfering with glomerular filter integrity.Competing Interest StatementA.G. has financial interest in Goldfinch Biopharma, which was reviewed and is managed by Brigham and Womens Hospital, Mass General Brigham, the Broad Institute and Harvard University in accordance with their conflict of interest policies. A.J.B.W., K.H.K., A.W., J.M.H and H.G.R. have filed a provisional patent Methods for identifying and treating patients with antibody-mediated acquired primary or recurrent idiopathic nephrotic syndrome.Funding StatementA.J.B.W. was supported by T32 training fellowships T32HL007627 and T32DK007527. A.W. was supported by an Eleanor Miles Shore Fellowship by Harvard Medical School and is a current recipient of a NephCure/NEPTUNE ancillary study award. G.L. is supported by NIH grant DK007053-45S1. A.G. is supported by NIH grants DK099465 and DK095045. S.W. is supported by NIH grants U01DK085660, U01DK104308, and UG3DK114915. M.S. is supported by NIH grant R01DK119380 and R01DK1088085.The Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54-DK-083912, is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through a collaboration between the Office of Rare Diseases Research (ORDR), NCATS, and the National Institute of Diabetes, Digestive, and Kidney Diseases. Additional funding and/or programmatic support for this project has also been provided by the University of Michigan, the NephCure Kidney International and the Halpin Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mass General Brigham (MGB) Institutional Review Board has approved all studies within this manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in this manuscript are available upon request from the corresponding author (aweins{at}bwh.harvard.edu). ER -